SELLAS Life Sciences (SLS) Intangibles (2013 - 2017)

SELLAS Life Sciences (SLS) posted quarterly Intangibles of $17.6 million for Q4 2017, up 26.2% quarter-over-quarter from $13.9 million in Q2 2015.

SELLAS Life Sciences (SLS) Intangibles (2013 - 2017) Analysis & Trends

SELLAS Life Sciences (SLS) has reported Intangibles for 4 consecutive years, with $17.6 million the latest figure, recorded in Q4 2017.

In Q4 2017, Intangibles changed N/A year-over-year to $17.6 million; the TTM figure through Dec 2017 stood at $17.6 million (changed N/A YoY), while the FY2017 annual figure was $17.6 million, changed N/A from the prior year.
Intangibles rose to $17.6 million in Q4 2017 per SLS's latest filing, from $13.9 million in the prior quarter.
Across five years, Intangibles topped out at $17.6 million in Q4 2017 and bottomed at $13.9 million in Q2 2015.
Historically, Intangibles has averaged $15.0 million across 4 years, with a median of $14.9 million in 2014.
Annual changes were most pronounced in 2014 — Intangibles fell 1.35% — and 2015, when it decreased 5.67%.
SELLAS Life Sciences' Intangibles stood at $15.0 million in 2013, then dropped by 2.98% to $14.5 million in 2014, then slipped by 4.04% to $13.9 million in 2015, then advanced by 26.2% to $17.6 million in 2017.
Business Quant data shows SLS's Intangibles at $17.6 million in Q4 2017, $13.9 million in Q2 2015, and $14.4 million in Q1 2015.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Intangibles (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	412.80 Mn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	1.31 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	266.00 Mn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	63.28 Mn
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	60.96 Mn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	93.49 Mn
10	SELLAS Life Sciences	2.32 Bn	2.18 Bn	-	-

Download Data